{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dabrafenib+75+mg+capsule",
    "query": {
      "intervention": "Dabrafenib 75 mg capsule"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dabrafenib+75+mg+capsule&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T19:44:27.244Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03332589",
      "title": "E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Melanoma",
        "Brain Metastases"
      ],
      "interventions": [
        {
          "name": "E6201",
          "type": "DRUG"
        },
        {
          "name": "E6201 plus dabrafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spirita Oncology, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-07-02",
      "completion_date": "2021-10-11",
      "has_results": true,
      "last_update_posted_date": "2022-05-20",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 1,
      "location_summary": "Tucson, Arizona",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03332589"
    },
    {
      "nct_id": "NCT01231568",
      "title": "An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Regimen D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2010-10-21",
      "completion_date": "2011-05-13",
      "has_results": false,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231568"
    },
    {
      "nct_id": "NCT01978236",
      "title": "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma and Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Dabrafenib 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Trametinib 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-04-08",
      "completion_date": "2017-04-26",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01978236"
    },
    {
      "nct_id": "NCT01336634",
      "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 177,
      "start_date": "2011-08-05",
      "completion_date": "2021-01-07",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Orange, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01336634"
    },
    {
      "nct_id": "NCT01738451",
      "title": "A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2118436 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-01-22",
      "completion_date": "2014-11-28",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01738451"
    },
    {
      "nct_id": "NCT01750918",
      "title": "BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Panitumumab",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2012-12-19",
      "completion_date": "2020-06-18",
      "has_results": true,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01750918"
    },
    {
      "nct_id": "NCT01340833",
      "title": "Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2118436",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-06-08",
      "completion_date": "2011-09-12",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01340833"
    },
    {
      "nct_id": "NCT02082665",
      "title": "Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin10 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Midazolam 3 mg syrup",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib 75 mg capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2015-02-19",
      "completion_date": "2016-08-01",
      "has_results": false,
      "last_update_posted_date": "2017-07-24",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082665"
    },
    {
      "nct_id": "NCT01677741",
      "title": "A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Brain"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Months to 17 Years"
      },
      "enrollment_count": 85,
      "start_date": "2013-05-23",
      "completion_date": "2020-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-11-24",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01677741"
    },
    {
      "nct_id": "NCT02039947",
      "title": "Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma and Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2014-02-21",
      "completion_date": "2018-02-14",
      "has_results": true,
      "last_update_posted_date": "2019-05-21",
      "last_synced_at": "2026-09-26T19:44:27.244Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039947"
    }
  ]
}